4 papers in the library · 28 citations · publishing 2023-2026
European Neuropsychopharmacology February 15, 2023 Santiago Madero, O. D. Alvarez 12 citations
The COVID-19 pandemic has had widespread effects on health, society, and the economy. The text does not provide specific findings, arguments, or data beyond referencing the pandemic itself.
Lancet Reg Health Eur November 20, 2025 Santiago Madero, Oscar Soto-Angona, Genís Ona et al. 9 citations
Psychedelic-assisted therapy in Europe is gaining momentum through recent initiatives in Switzerland, Germany, and the Czech Republic, though access remains limited. The authors argue for an integrative framework that considers neurobiological mechanisms, subjective experience, and contextual factors, emphasizing how effects involving neuroplasticity and critical periods may interact with psychotherapeutic processes. Context and psychological support are highlighted as crucial for shaping outcomes. Regulatory fragmentation and methodological complexities hinder progress, but publicly funded trials such as EPIsoDE and PsyPal offer promising examples of ethical and effective approaches. The future of psychedelic therapy lies in embracing its complexity.
Dialogues in clinical neuroscience December 1, 2025 Ivona-Maria Tudorancea, Gabriela-Dumitrita Stanciu, Carla Torrent et al. 4 citations
As the global population ages, depression in older adults is increasingly common, yet conventional antidepressants often have limited effectiveness and problematic side effects. Psychedelic compounds are emerging as a potential alternative. This review examines preclinical and clinical evidence suggesting psychedelics could treat major depressive disorder in the elderly. It discusses the neurobiological mechanisms behind these effects, highlights relevant animal models, and addresses safety concerns. The authors propose strategies to improve the efficacy and safety of psychedelic therapy in future clinical trials, offering a new avenue for treating late-life depression.
JAMA Psychiatry March 25, 2026 Wiesław Jerzy Cubała, Malek Bajbouj, Michael Bauer et al. 3 citations
A single day of treatment with an inhaled synthetic formulation of mebufotenin (GH001) significantly reduced depression symptoms in adults with treatment-resistant depression compared to placebo. In a randomized, double-blind trial of 81 patients, those receiving up to three escalating doses of GH001 showed an average 15.5-point greater improvement on the Montgomery-Åsberg Depression Rating Scale by day 8 than those on placebo. Remission rates were 57.5% for GH001 and 0% for placebo. No severe or serious adverse events occurred. The findings suggest GH001 may be a rapid-acting, well-tolerated treatment option for treatment-resistant depression.